Company Filing History:
2 out of 93 
2 out of 1,295 
1 out of 1 Years Active: 2014-2019
Title: Joachim Hauber: Innovator in Retrovirus Research
Introduction
Joachim Hauber is a renowned inventor based in Hamburg, Germany, who has significantly contributed to the field of retrovirus research. With a total of three patents to his name, Hauber is particularly known for his work on tailored recombinases that have potential therapeutic applications in treating retrovirus infections, including HIV.
Latest Patents
Hauber's innovative work includes two significant patents focusing on tailored recombinases. The first patent details a method for preparing an expression vector encoding a tailored recombinase capable of recombining asymmetric target sequences within the long terminal repeat (LTR) of proviral DNA from various retrovirus strains. This invention presents promising pharmaceutical compositions aimed at treating and preventing retrovirus infections, particularly those caused by HIV. The second patent emphasizes the development of a well-tolerated and highly specific tailored recombinase. This recombinase is effective in recombining asymmetric target sequences across more than 90% of HIV strains, excising HIV-1 sequences and thereby providing potential therapeutic benefits.
Career Highlights
Hauber has worked at prestigious institutions, including Technische Universität Dresden and the Max Planck Society for the Advancement of Science. His experience in these prominent research organizations has provided him with a robust foundation in the field of molecular biology and virology.
Collaborations
Throughout his career, Joachim Hauber has collaborated with esteemed colleagues, including Frank Buchholz and Jan Chemnitz. These collaborations have supplemented his research endeavors and have contributed to the advancement of innovative methodologies in retrovirus treatment.
Conclusion
Joachim Hauber remains a key figure in the development of innovative solutions for retrovirus infections. His patents not only reflect his expertise but also showcase his commitment to contributing to the scientific community and improving health outcomes through targeted therapies.